HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief

This article was originally published in The Rose Sheet

Executive Summary

Avon Products Inc. says the SEC has closed one investigation into the company. More news in brief.

You may also be interested in...



Red Door Spa Debuts “Professional” Namesake Line For Home Use

Red Door Spa launches its first product line aimed at the consumer market. The “professional-grade” collections are intended to “deliver innovation and added value to our guests and extend their spa experience and results at home,” according to CEO Todd Walter.

Waking The “Sleeping Giant”: New Elizabeth Arden Brand To Launch This Fall

Elizabeth Arden plans to roll out its repackaged, repositioned namesake brand to 50 flagship stores around the globe in September, with a broader launch to follow. Firm aims to rectify what it sees as a glaring incongruity: that Elizabeth Arden has a global awareness ranking in the top five, yet is ranked 15th as a global brand. Ultimately, the move should more than double Arden’s retail business, the firm says.

Avon Clearing the Decks: Firm Ousts Cramb Amid Ongoing Investigation

Avon announces dismissal of Vice Chairman Charles Cramb in connection with firm’s internal investigation into possible breach of fiduciary duty and alleged violations of the Foreign Corrupt Practices Act. With CEO Andrea Jung on her way out as well, analysts see in the decay of Avon’s upper management glimmers of opportunity.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018281

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel